AGENT ENHANCING LIPID-LOEWRING EFFECT

It is intended to provide a drug which has an excellent effect of inhibiting the secretion of apoB-related lipoproteins and enhances the lipid-lowering effect of another lipid-lowering agent, i.e., an agent enhancing lipid-lowering effect. It is found out that a derivative having tetrahydropyran rep...

Full description

Saved in:
Bibliographic Details
Main Authors MIURA, MASANORI, SUGA, AKIRA, MORITANI, HIROSHI, SASUGA, DAISUKE, KUBOTA, HIDEKI
Format Patent
LanguageEnglish
French
Japanese
Published 09.06.2005
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
Abstract It is intended to provide a drug which has an excellent effect of inhibiting the secretion of apoB-related lipoproteins and enhances the lipid-lowering effect of another lipid-lowering agent, i.e., an agent enhancing lipid-lowering effect. It is found out that a derivative having tetrahydropyran represented by the following general formula (I): (I) wherein each symbol is as defined in the description; has a potent activity of inhibiting the secretion of apoB-related lipoproteins and can enhance the lipid-lowering effect of another lipid-lowering agent, when used together with such an agent. When used together with another lipid-lowering agent, the above drug is useful as an agent enhancing lipid-lowering effect for familial hypercholesterolemia and a remedy for intractable hyperlipemia with the coincidence of diabetes. L'invention concerne un agent renforçant l'effet hypolipidémiant, à savoir un médicament présentant un excellent effet d'inhibition de la sécrétion des lipoprotéines associées à apoB, et renforçant l'effet hypolipidémiant d'un autre agent hypolipidémiant. Selon l'invention, un dérivé contenant du tétrahydropyrane, représenté par la formule générale (I) : (I), dans laquelle chaque symbole est tel que défini dans la description, présente une activité puissante d'inhibition de la sécrétion des lipoprotéines associées à apoB, et peut renforcer l'effet hypolipidémiant d'un autre agent hypolipidémiant lorsqu'il est utilisé avec cet autre agent. Lorsqu'il est combiné avec un autre agent hypolipidémiant, le médicament selon l'invention est utilisé en tant qu'agent renforçant l'effet hypolipidémiant, dans le traitement de l'hypercholestérolémie familiale et de l'hyperlipémie rebelle accompagnant le diabète.
AbstractList It is intended to provide a drug which has an excellent effect of inhibiting the secretion of apoB-related lipoproteins and enhances the lipid-lowering effect of another lipid-lowering agent, i.e., an agent enhancing lipid-lowering effect. It is found out that a derivative having tetrahydropyran represented by the following general formula (I): (I) wherein each symbol is as defined in the description; has a potent activity of inhibiting the secretion of apoB-related lipoproteins and can enhance the lipid-lowering effect of another lipid-lowering agent, when used together with such an agent. When used together with another lipid-lowering agent, the above drug is useful as an agent enhancing lipid-lowering effect for familial hypercholesterolemia and a remedy for intractable hyperlipemia with the coincidence of diabetes. L'invention concerne un agent renforçant l'effet hypolipidémiant, à savoir un médicament présentant un excellent effet d'inhibition de la sécrétion des lipoprotéines associées à apoB, et renforçant l'effet hypolipidémiant d'un autre agent hypolipidémiant. Selon l'invention, un dérivé contenant du tétrahydropyrane, représenté par la formule générale (I) : (I), dans laquelle chaque symbole est tel que défini dans la description, présente une activité puissante d'inhibition de la sécrétion des lipoprotéines associées à apoB, et peut renforcer l'effet hypolipidémiant d'un autre agent hypolipidémiant lorsqu'il est utilisé avec cet autre agent. Lorsqu'il est combiné avec un autre agent hypolipidémiant, le médicament selon l'invention est utilisé en tant qu'agent renforçant l'effet hypolipidémiant, dans le traitement de l'hypercholestérolémie familiale et de l'hyperlipémie rebelle accompagnant le diabète.
Author MIURA, MASANORI
KUBOTA, HIDEKI
SUGA, AKIRA
MORITANI, HIROSHI
SASUGA, DAISUKE
Author_xml – fullname: MIURA, MASANORI
– fullname: SUGA, AKIRA
– fullname: MORITANI, HIROSHI
– fullname: SASUGA, DAISUKE
– fullname: KUBOTA, HIDEKI
BookMark eNrjYmDJy89L5WRQdXR39QtRcPXzcPRz9vRzV_DxDPB00fXxdw0PAnFd3dxcnUN4GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakl8uL-RgYGpgamhsYWRo6ExcaoAA7oluw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate AGENT RENFORÇANT L'EFFET HYPOLIPIDEMIANT
Edition 7
ExternalDocumentID WO2005051382A1
GroupedDBID EVB
ID FETCH-epo_espacenet_WO2005051382A13
IEDL.DBID EVB
IngestDate Fri Jul 19 11:47:44 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
Japanese
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_WO2005051382A13
Notes Application Number: WO2004JP17899
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050609&DB=EPODOC&CC=WO&NR=2005051382A1
ParticipantIDs epo_espacenet_WO2005051382A1
PublicationCentury 2000
PublicationDate 20050609
PublicationDateYYYYMMDD 2005-06-09
PublicationDate_xml – month: 06
  year: 2005
  text: 20050609
  day: 09
PublicationDecade 2000
PublicationYear 2005
RelatedCompanies MIURA, MASANORI
KUBOTA, HIDEKI
SUGA, AKIRA
YAMANOUCHI PHARMACEUTICAL CO., LTD
MORITANI, HIROSHI
SASUGA, DAISUKE
RelatedCompanies_xml – name: MORITANI, HIROSHI
– name: SUGA, AKIRA
– name: KUBOTA, HIDEKI
– name: YAMANOUCHI PHARMACEUTICAL CO., LTD
– name: MIURA, MASANORI
– name: SASUGA, DAISUKE
Score 2.7063158
Snippet It is intended to provide a drug which has an excellent effect of inhibiting the secretion of apoB-related lipoproteins and enhances the lipid-lowering effect...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title AGENT ENHANCING LIPID-LOEWRING EFFECT
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20050609&DB=EPODOC&locale=&CC=WO&NR=2005051382A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQSTNISjZPNUvRtTQAHaqdbGasm2iQbKJrlmSeaJJsngZsQ4PGO3z9zDxCTbwiTCOYGHJge2HA54SWgw9HBOaoZGB-LwGX1wWIQSwX8NrKYv2kTKBQvr1biK2LGqx3DDouz1LNxcnWNcDfxd9ZzdkZ2G9T8wuCyJmCDtxzBPaVWEENadBJ-65hTqB9KQXIlYqbIANbANC8vBIhBqasRGEGTmfY3WvCDBy-0ClvIBOa-4pFGFQd3V39QhRc_TxAq-v83BWAvXJPF10ff9dw0JoGBWCb09U5RJRB2c01xNlDF2hfPNx78eH-yI4zFmNgAXb8UyUYFMzTLFItQdOCacZpJonmpsBAtDBPSUoCNsoMEtMsDCQZZPCZJIVfWpqBC3wMKWhEwVKGgaWkqDRVFljBliTJgcMFAANYea8
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsWPqQW1b8VCP9I-DNnadJ226ZDq9lbargFFdLiK_76XuOqe9hYSyMfB5e53d_kF4JrrRUkqe665uiDVLm1Dy_XS1OyC5GZJOPrQIt4RMzt8Mu9n1qwFb81bGMkT-i3JEVGjStT3Wt7Xi_8gli9rK5e3xQt2fdwFad9XG3Qs6PJc1R_26STxE0_1PMRtKnv8HbME4d4AsdIWEfy8wnl6Hop3KYt1oxLswfYE53uv96H1mneh4zV_r3VhJ16lvLG50r7lAdwMRpSlCmWhqK5jIwVR-djXooRORU2Dgj4n9dJDuApo6oUarpf9HS-bJuubM46gjcC_OgaFcKdyRVqQG9zMiYVCdMi8KNAp03Pu6CfQ2zTT6ebhS-iEaRxl0Zg9nMGupCQV0QW3B-3686s6R2NbFxdSRj_b7Hyc
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=AGENT+ENHANCING+LIPID-LOEWRING+EFFECT&rft.inventor=MIURA%2C+MASANORI&rft.inventor=SUGA%2C+AKIRA&rft.inventor=MORITANI%2C+HIROSHI&rft.inventor=SASUGA%2C+DAISUKE&rft.inventor=KUBOTA%2C+HIDEKI&rft.date=2005-06-09&rft.externalDBID=A1&rft.externalDocID=WO2005051382A1